Results 4,681-4,700 of 11,255 for speaker:Colm Burke

Written Answers — Department of Health: Health Services (12 Jul 2022)

Colm Burke: 831. To ask the Minister for Health the drug reimbursement decisions that have been made by the HSE drugs group and executive management team respectively in each of its meetings from January 2018 to date in tabular form; and if he will make a statement on the matter. [37271/22]

Written Answers — Department of Health: Hospital Staff (12 Jul 2022)

Colm Burke: 969. To ask the Minister for Health the action that will be taken by his Department and the HSE in respect of the employment of 20 additional clinical nurse specialists to assist those waiting for a neurology outpatient appointment as advocated by Neurological Alliance of Ireland; and if he will make a statement on the matter. [37796/22]

Written Answers — Department of Health: Hospital Services (12 Jul 2022)

Colm Burke: 970. To ask the Minister for Health if additional funding will be provided to support eye care services in Cork, particularly to ensure that there is greater capacity for services in Cork to assist those with serious conditions such as glaucoma to have more regular care; and if he will make a statement on the matter. [37797/22]

Written Answers — Department of Health: Hospital Appointments Status (12 Jul 2022)

Colm Burke: 971. To ask the Minister for Health if he will confirm that a glaucoma patient (details supplied) will receive an ophthalmology appointment with a specialist in Cork in the near future, as their sight is rapidly deteriorating and that additional funding will be made available for patients in similar circumstances in Cork, that they might receive more regular treatment; and if he will make a...

Written Answers — Department of Health: Medicinal Products (12 Jul 2022)

Colm Burke: 974. To ask the Minister for Health if his Department has completed the review of a report (details supplied) in respect of the drug reimbursement process; when this report and the key recommendations are expected to be published; the reason for the continued delay in publishing this report given that Covid-19 is no longer as large a public health risk as it once was; and if he will make a...

Written Answers — Department of Health: Medicinal Products (12 Jul 2022)

Colm Burke: 975. To ask the Minister for Health the reason that a report (details supplied) submitted to the Minister in January 2020 at a cost of €86,000 has still not been published; if he will commit to prioritising the review and publication of same; and if he will make a statement on the matter. [37811/22]

Written Answers — Department of Health: Health Strategies (12 Jul 2022)

Colm Burke: 976. To ask the Minister for Health the status of implementation of the key actions outlined in the National Rare Disease Plan 2014-2018; the timeline for the implementation of remaining actions; when a successor plan will be published; and if he will make a statement on the matter. [37812/22]

Written Answers — Department of Health: Health Strategies (12 Jul 2022)

Colm Burke: 977. To ask the Minister for Health if his Department intends to follow through on the programme for Government’s clear commitment to publish a successor plan to the National Rare Disease Plan 2014–2018; the reasons for the delay in prioritising all remaining actions; and if he will make a statement on the matter. [37813/22]

Written Answers — Department of Health: Health Strategies (12 Jul 2022)

Colm Burke: 978. To ask the Minister for Health the work that has been done to prioritise the remaining actions in the National Rare Disease Plan 2014-2018; the deadlines for implementing these actions; the progress that has been made to date; and if he will make a statement on the matter. [37814/22]

Written Answers — Department of Health: Health Strategies (12 Jul 2022)

Colm Burke: 979. To ask the Minister for Health if a new liaison person within his Department has been appointed to oversee implementation of the National Rare Disease Plan; if a review conducted by the former liaison person will be published; and if he will make a statement on the matter. [37815/22]

Written Answers — Department of Health: Health Strategies (12 Jul 2022)

Colm Burke: 992. To ask the Minister for Health if a position has been identified within his Department that focuses solely on rare disease policy; if he plans to establish such a position for rare disease policy; and if he will make a statement on the matter. [37832/22]

Written Answers — Department of Health: Health Strategies (12 Jul 2022)

Colm Burke: 993. To ask the Minister for Health the status of all programme for Government commitments to ensure an increased focus on rare diseases as outlined in the programme for Government; and if he will make a statement on the matter. [37834/22]

Written Answers — Department of Health: Medicinal Products (12 Jul 2022)

Colm Burke: 980. To ask the Minister for Health the extent of engagement that he has had with his Department officials on the Health (Pricing and Supply of Medical Goods) (Amendment) Private Members Bill 2021 that is due for Committee Stage; and if he will make a statement on the matter. [37816/22]

Written Answers — Department of Health: Medicinal Products (12 Jul 2022)

Colm Burke: 981. To ask the Minister for Health his views on the Health (Pricing and Supply of Medical Goods) (Amendment) Bill 2021; if he supports the proposed amendment to the Health Act 2013; and if he will make a statement on the matter. [37817/22]

Written Answers — Department of Health: Medicinal Products (12 Jul 2022)

Colm Burke: 984. To ask the Minister for Health if he intends to amend the Health Act 2013 to account for the unique context surrounding orphan medicinal products and advanced therapy medicinal products such as gene therapy; and if he will make a statement on the matter. [37820/22]

Written Answers — Department of Health: Medicinal Products (12 Jul 2022)

Colm Burke: 986. To ask the Minister for Health the steps that can be taken to expedite the drug reimbursement process to account for the life-threatening nature of rare diseases; if he plans to make changes to the reimbursement process in Ireland that would enable expedited access for patients with severe unmet needs; and if he will make a statement on the matter. [37822/22]

Written Answers — Department of Health: Medicinal Products (12 Jul 2022)

Colm Burke: 989. To ask the Minister for Health his views on the continued use of the quality-adjusted life year threshold in respect of the drug reimbursement process; if his attention has been drawn to the negative consequences of the use of the QALY as a cost-effectiveness tool can have on serving the unmet needs of rare disease patients; and if he will make a statement on the matter. [37829/22]

Written Answers — Department of Health: Medicinal Products (12 Jul 2022)

Colm Burke: 983. To ask the Minister for Health if Ireland is currently in breach of the European Union Transparency Directive 89/105/EEC; if his Department intends to reduce the ongoing delays for patients to gain access to European Medicines Agency-approved medicine in Ireland; and if he will make a statement on the matter. [37819/22]

Written Answers — Department of Health: Medicinal Products (12 Jul 2022)

Colm Burke: 985. To ask the Minister for Health the work that is being carried out to enhance transparency and improve communication with patient groups and industry during the drug reimbursement process; if he will provide a mechanism for patient groups and industry to establish communication with the HSE corporate pharmaceutical unit throughout the reimbursement process; and if he will make a statement...

Written Answers — Department of Health: Medicinal Products (12 Jul 2022)

Colm Burke: 987. To ask the Minister for Health if his Department has examined international best practice such as those in Scotland and Germany on the matter of interim and early access reimbursement models; and if he will make a statement on the matter. [37823/22]